英诺特10月15日获融资买入259.17万元，融资余额1.77亿元

Core Viewpoint - Innotech's stock performance shows a slight increase of 0.30% on October 15, with a trading volume of 42.12 million yuan, indicating a low financing balance compared to historical levels [1] Financing Summary - On October 15, Innotech had a financing buy amount of 2.59 million yuan and a financing repayment of 5.10 million yuan, resulting in a net financing buy of -2.50 million yuan [1] - As of October 15, the total financing and securities lending balance for Innotech was 17.7 million yuan, which accounts for 8.39% of its circulating market value, indicating a low financing balance below the 20th percentile of the past year [1] - There were no shares sold or repaid in the securities lending segment on October 15, with a total securities lending balance of 0.00 yuan, placing it in the high range above the 80th percentile of the past year [1] Business Performance Summary - As of June 30, Innotech had 7,269 shareholders, a decrease of 2.94% from the previous period, while the average number of circulating shares per person increased by 3.03% to 9,466 shares [2] - For the first half of 2025, Innotech reported an operating income of 276 million yuan, a year-on-year decrease of 34.35%, and a net profit attributable to shareholders of 125 million yuan, down 39.36% year-on-year [2] - Since its A-share listing, Innotech has distributed a total of 152 million yuan in dividends [2] Company Overview - Innotech, established on February 6, 2006, and listed on July 28, 2022, is located in Fengtai District, Beijing, specializing in the research, production, and sales of POCT rapid diagnostic products [1] - The company's main revenue sources include respiratory series products (96.49%), other reagent series (2.99%), and preconception care series (0.51%) [1]